If participant agrees to take part in this study, they will continue to receive ruxolitinib as prescribed in Study 2007-0169. In addition, participant will have study visits (described below) to help researchers collect data about any side effects they may be having and what effect, if any, ruxolitinib is having on them and/or the disease.